New York University Clinical Cancer Center
New York, New York 10065
1 studies enrolling now · 20 studies all time
What they study most
Advanced Malignancies, Bladder Cancer, Brain Cancer, Brain Tumor, Breast Cancer, Carcinoma, Colorectal Cancer, Cutaneous Melanoma, Fallopian Tube Cancer, GBM, Glioblastoma, Glioblastoma Multiforme
Studies at this site
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer — Recruiting now
- A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma — Completed
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Running, not enrolling
- Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients — Running, not enrolling
- Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) — Running, not enrolling
- Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer — Completed
- A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors — Completed
- Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer — Completed
- Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer — Stopped early
- Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer — Stopped early
- A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies — Completed
- Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer — Completed
- Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer — Status unconfirmed
- Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry — Completed
- Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma — Stopped early
- Early Diagnosis of Pulmonary Nodules — Completed
- Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma — Stopped early
- PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer — Completed
- Irinotecan and Bevacizumab for Recurrent Ovarian Cancer — Completed
- BMS-247550 in Treating Patients With Stage IV Melanoma — Completed